{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:18Z","timestamp":1793305518635,"version":"4.5.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an innovative form of taxane that has superior antitumor effects; however, the safety profile between nab-paclitaxel and traditional taxanes remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the burden of adverse events (AEs) in patients with multiple malignancies receiving nab-paclitaxel compared with that in patients receiving traditional taxanes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Randomized clinical trials comparing nab-paclitaxel with traditional taxanes (solvent-based paclitaxel [sb-paclitaxel] or docetaxel) in the treatment of primary solid-organ malignancies were included if AEs were reported as an outcome. Statistical analyses were conducted to calculate the summary odds ratio (OR) of the relevant adverse outcomes related to nab-paclitaxel and traditional taxanes. Prespecified subgroup analyses based on intervention and doses, primary tumor sites, and different ethnic groups were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twelve clinical trials were included in the meta-analysis. Grade 3\/4 anemia, thrombocytopenia, and neurotoxicity were more frequent with nab-paclitaxel than with traditional taxanes. Nab-paclitaxel at 100 or 125 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/w dosage was associated with fewer or similar grade 3\/4 specific AEs. Allergy was less common with nab-paclitaxel. The median recovery times of neurotoxicity were 25, 64, and 37 days in patients receiving nab-paclitaxel, sb-paclitaxel, and docetaxel, respectively. Elevated incidences of specific AEs were more common in breast cancer and non-Asian patients than in other malignancies and ethnic groups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Nab-paclitaxel increased the risk of hematologic and non-hematologic AEs in general, but anaphylaxis was less common, and the recovery duration of neurotoxicity was shorter. Weekly administration of nab-paclitaxel at a lower dosage provided better tolerance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211058385","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:30:54Z","timestamp":1640737854000},"page":"898-909","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.1177","volume":"56","author":[{"given":"Fei","family":"He","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-1266","authenticated-orcid":false,"given":"Qiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"bibr1-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1023\/a:1010618632738"},{"key":"bibr2-10600280211058385","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342070-00005"},{"key":"bibr3-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0424-z"},{"key":"bibr4-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.07.004"},{"key":"bibr5-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8416-0"},{"key":"bibr6-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.8.1041"},{"key":"bibr7-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.937"},{"key":"bibr8-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.7.919"},{"key":"bibr9-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-1634"},{"key":"bibr10-10600280211058385","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S13836"},{"key":"bibr11-10600280211058385","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18900"},{"key":"bibr12-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064"},{"key":"bibr13-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"bibr14-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9092"},{"key":"bibr15-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000"},{"key":"bibr16-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5152"},{"key":"bibr17-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"bibr18-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30689-8"},{"key":"bibr19-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)04149-5"},{"key":"bibr20-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.5397"},{"key":"bibr21-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2009.01235.x"},{"key":"bibr22-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.5298"},{"key":"bibr23-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13221"},{"key":"bibr24-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4200-1"},{"key":"bibr25-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4612"},{"key":"bibr26-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.06.012"},{"key":"bibr27-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0664"},{"key":"bibr28-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.5848"},{"key":"bibr29-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.08.003"},{"key":"bibr30-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3927"},{"key":"bibr31-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30219-9"},{"key":"bibr32-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"bibr33-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6"},{"key":"bibr34-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"bibr35-10600280211058385","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0074"},{"key":"bibr36-10600280211058385","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.00.6148"},{"key":"bibr37-10600280211058385","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2007.n.049"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211058385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211058385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211058385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:35Z","timestamp":1777374995000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211058385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/10600280211058385"],"URL":"https:\/\/doi.org\/10.1177\/10600280211058385","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}